Recent advances in novel miRNA mediated approaches for targeting breast cancer.

IF 4.3 4区医学 Q1 PHARMACOLOGY & PHARMACY Journal of Drug Targeting Pub Date : 2023-09-01 DOI:10.1080/1061186X.2023.2240979

Seyedeh Melika Ahmadi, Shervin Amirkhanloo, Rezvan Yazdian-Robati, Hossein Ebrahimi, Faezeh Hosseini Pirhayati, Waleed H Almalki, Pedram Ebrahimnejad, Prashant Kesharwani

{"title":"Recent advances in novel miRNA mediated approaches for targeting breast cancer.","authors":"Seyedeh Melika Ahmadi, Shervin Amirkhanloo, Rezvan Yazdian-Robati, Hossein Ebrahimi, Faezeh Hosseini Pirhayati, Waleed H Almalki, Pedram Ebrahimnejad, Prashant Kesharwani","doi":"10.1080/1061186X.2023.2240979","DOIUrl":null,"url":null,"abstract":"<p><p>Breast cancer (BC) is considered one of the most frequent cancers among woman worldwide. While conventional therapy has been successful in treating many cases of breast cancer, drug resistance, heterogenicity, tumour features and recurrence, invasion, metastasis and the presence of breast cancer stem cells can hinder the effect of treatments, and can reduce the quality of life of patients. MicroRNAs (miRNAs) are short non-coding RNA molecules that play a crucial role in the development and progression of breast cancer. Several studies have reported that aberrant expression of specific miRNAs is associated with the pathogenesis of breast cancer. However, miRNAs are emerging as potential biomarkers and therapeutic targets for breast cancer. Understanding their role in breast cancer biology could help develop more effective treatments for this disease. The present study discusses the biogenesis and function of miRNAs, as well as miRNA therapy approaches for targeting and treating breast cancer cells.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Targeting","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1061186X.2023.2240979","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 2

Abstract

Breast cancer (BC) is considered one of the most frequent cancers among woman worldwide. While conventional therapy has been successful in treating many cases of breast cancer, drug resistance, heterogenicity, tumour features and recurrence, invasion, metastasis and the presence of breast cancer stem cells can hinder the effect of treatments, and can reduce the quality of life of patients. MicroRNAs (miRNAs) are short non-coding RNA molecules that play a crucial role in the development and progression of breast cancer. Several studies have reported that aberrant expression of specific miRNAs is associated with the pathogenesis of breast cancer. However, miRNAs are emerging as potential biomarkers and therapeutic targets for breast cancer. Understanding their role in breast cancer biology could help develop more effective treatments for this disease. The present study discusses the biogenesis and function of miRNAs, as well as miRNA therapy approaches for targeting and treating breast cancer cells.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

靶向乳腺癌的新型miRNA介导方法的最新进展。

乳腺癌(BC)被认为是全世界女性中最常见的癌症之一。虽然传统疗法在治疗许多乳腺癌病例方面取得了成功，但耐药、异质性、肿瘤特征和复发、侵袭、转移以及乳腺癌干细胞的存在会阻碍治疗的效果，并降低患者的生活质量。MicroRNAs (miRNAs)是一种短的非编码RNA分子，在乳腺癌的发生和发展中起着至关重要的作用。一些研究报道了特定mirna的异常表达与乳腺癌的发病机制有关。然而，mirna正在成为乳腺癌的潜在生物标志物和治疗靶点。了解它们在乳腺癌生物学中的作用有助于开发更有效的治疗方法。本研究讨论了miRNA的生物发生和功能，以及miRNA靶向和治疗乳腺癌细胞的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Drug Targeting 医学-药学

CiteScore

9.10

自引率

0.00%

发文量

165

审稿时长

2 months

期刊介绍： Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs. Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns.